- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 5/08 - Tripeptides
Détention brevets de la classe C07K 5/08
Brevets de cette classe: 696
Historique des publications depuis 10 ans
|
30
|
31
|
42
|
32
|
36
|
30
|
27
|
27
|
18
|
19
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Purdue Research Foundation | 3705 |
27 |
| Bristol-myers Squibb Company | 4847 |
15 |
| ISP Investments Inc. | 455 |
15 |
| Ajinomoto Co., Inc. | 2307 |
10 |
| Hoffmann-La Roche Inc. | 3511 |
8 |
| The Regents of the University of California | 20211 |
8 |
| Onyx Therapeutics, Inc. | 69 |
8 |
| Genentech, Inc. | 4017 |
7 |
| Novartis AG | 10674 |
6 |
| Boehringer Ingelheim International GmbH | 4649 |
6 |
| Novozymes A/S | 3336 |
6 |
| Regeneron Pharmaceuticals, Inc. | 4394 |
6 |
| Merck Sharp & Dohme LLC | 3739 |
6 |
| DSM IP Assets B.V. | 5557 |
5 |
| Agency for Science, Technology and Research | 3661 |
5 |
| InterMune, Inc. | 52 |
5 |
| MedImmune Limited | 625 |
5 |
| Rhythm Pharmaceuticals, Inc. | 79 |
5 |
| Obschestvo S Ogranichennoi Otvetstvennostyu "SIA Peptides" | 6 |
5 |
| California Institute of Technology | 3991 |
4 |
| Autres propriétaires | 534 |